EVAX NASDAQ
Evaxion Biotech A/S
1W: -4.2%
1M: +4.2%
3M: -5.3%
YTD: -32.1%
1Y: -27.9%
3Y: -92.4%
5Y: -99.3%
$3.20
+0.02 (+0.63%)
Weekly Expected Move ±5.9%
$3
$3
$3
$3
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$8M
+125.8% ▲
Gross Profit
$8M
+125.1% ▲
Operating Income
-$9M
+37.1% ▲
Net Income
-$8M
+26.8% ▲
EPS (Diluted)
$-1.21
+87.7% ▲
EBITDA
-$9M
+11.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $73K | $3M | $8M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +4480.8% | +125.8% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $73K | $3M | $8M |
| Gross Margin | — | — | 100.0% | 100.0% | 99.7% |
| R&D Expenses | $20M | $17M | $12M | $10M | $10M |
| SG&A Expenses | $6M | $8M | $10M | $7M | $7M |
| Operating Expenses | $26M | $25M | $22M | $18M | $17M |
| Operating Income | -$26M | -$25M | -$22M | -$15M | -$9M |
| Operating Margin | — | — | -30406.8% | -440.6% | -122.7% |
| Interest Expense | $915K | $2M | $897K | $962K | $879K |
| Income Before Tax | -$25M | -$24M | -$23M | -$11M | -$9M |
| Tax Expense | -$178K | -$772K | -$790K | -$788K | -$911K |
| Net Income | -$25M | -$23M | -$22M | -$11M | -$8M |
| Net Margin | — | — | -30308.2% | -316.0% | -102.4% |
| EPS (Diluted) | $-50.40 | $-39.20 | $-32.40 | $-9.80 | $-1.21 |
| EBITDA | -$24M | -$23M | -$21M | -$10M | -$9M |
| Shares Outstanding | 487328 | 590967 | 683395 | 1M | 6M |